WO2022271183A1 - Polymères amphiphiles à auto-assemblage en tant qu'agents anti-covid-19 - Google Patents
Polymères amphiphiles à auto-assemblage en tant qu'agents anti-covid-19 Download PDFInfo
- Publication number
- WO2022271183A1 WO2022271183A1 PCT/US2021/039050 US2021039050W WO2022271183A1 WO 2022271183 A1 WO2022271183 A1 WO 2022271183A1 US 2021039050 W US2021039050 W US 2021039050W WO 2022271183 A1 WO2022271183 A1 WO 2022271183A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- polymers
- nanoparticles
- comb polymer
- self
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 112
- 208000025721 COVID-19 Diseases 0.000 title description 4
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 28
- 229940002612 prodrug Drugs 0.000 claims abstract description 28
- 239000000651 prodrug Substances 0.000 claims abstract description 28
- 239000002105 nanoparticle Substances 0.000 claims abstract description 26
- 239000003443 antiviral agent Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims description 34
- 239000003446 ligand Substances 0.000 claims description 32
- -1 colcicine Chemical compound 0.000 claims description 26
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 12
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 10
- 229960004150 aciclovir Drugs 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 4
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 4
- 241001678559 COVID-19 virus Species 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- QDIMHKWNHMVDJB-WBAXXEDZSA-N PF-00835231 Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)C=1NC=2C=CC=C(C=2C=1)OC)C(=O)CO)[C@@H]1CCNC1=O QDIMHKWNHMVDJB-WBAXXEDZSA-N 0.000 claims description 4
- 229960002418 ivermectin Drugs 0.000 claims description 4
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims description 4
- 229960003439 mebendazole Drugs 0.000 claims description 4
- HTNPEHXGEKVIHG-ZJTJHKMLSA-N molnupiravir Chemical compound CC(C)C(=O)OC[C@H]1O[C@H](C(O)C1O)N1C=C\C(NC1=O)=N\O HTNPEHXGEKVIHG-ZJTJHKMLSA-N 0.000 claims description 4
- 229940075124 molnupiravir Drugs 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 101100496169 Arabidopsis thaliana CLH1 gene Proteins 0.000 claims description 3
- 101100044057 Mesocricetus auratus SYCP3 gene Proteins 0.000 claims description 3
- 101100080600 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nse6 gene Proteins 0.000 claims description 3
- 101150111293 cor-1 gene Proteins 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 229920001223 polyethylene glycol Polymers 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical group OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 150000003973 alkyl amines Chemical group 0.000 description 6
- 150000001412 amines Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- 238000007112 amidation reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000004883 caffeic acid Nutrition 0.000 description 5
- 150000007942 carboxylates Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- 239000011976 maleic acid Substances 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000006845 Michael addition reaction Methods 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000009435 amidation Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 229940074360 caffeic acid Drugs 0.000 description 4
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000569 multi-angle light scattering Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- OBDTYOCDTWYTGV-YFKPBYRVSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-sulfopropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CS(O)(=O)=O OBDTYOCDTWYTGV-YFKPBYRVSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001354243 Corona Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003118 drug derivative Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000012607 strong cation exchange resin Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000001575 tandem quadrupole mass spectrometry Methods 0.000 description 2
- ATVFTGTXIUDKIZ-YFKPBYRVSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-sulfanylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CS)C(O)=O ATVFTGTXIUDKIZ-YFKPBYRVSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HZNQSWJZTWOTKM-UHFFFAOYSA-N 2,3,4-trimethoxybenzoic acid Chemical class COC1=CC=C(C(O)=O)C(OC)=C1OC HZNQSWJZTWOTKM-UHFFFAOYSA-N 0.000 description 1
- CZPYBWSSNRMMCN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]etho Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO CZPYBWSSNRMMCN-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 1
- 108091008400 carbohydrate binding proteins Proteins 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- MFFWLPUTVHVELN-UHFFFAOYSA-N dichloromethane;propan-2-yl acetate Chemical compound ClCCl.CC(C)OC(C)=O MFFWLPUTVHVELN-UHFFFAOYSA-N 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 125000003099 maleoyl group Chemical group C(\C=C/C(=O)*)(=O)* 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229960001913 mecysteine Drugs 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- RMEDXVIWDFLGES-UHFFFAOYSA-N methyl 6-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1 RMEDXVIWDFLGES-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- RAFYDKXYXRZODZ-UHFFFAOYSA-N octanoyl octanoate Chemical compound CCCCCCCC(=O)OC(=O)CCCCCCC RAFYDKXYXRZODZ-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229920000575 polymersome Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the present invention relates to the fields of amphiphilic polymers, and specifically to biocompatible micelle-forming comb-type polymers.
- the invention also relates to the field of targeted antiviral agents.
- Amphiphilic block copolymers comprising a hydrophobic block and a hydrophilic block have been well studied in recent years, because of their capacity for self-assembly into a variety of nanostructures as the surrounding solvent is varied. See Cameron et al., Can. J. Chem./Rev. Can. Chim. 77:1311-1326 (1999).
- the hydrophobic compartment of an amphiphilic polymer has a tendency to self-assemble in order to avoid contact with water and to minimize the free interfacial energy of the system.
- the hydrophilic blocks form a hydrated “corona” in the aqueous environment, and so the aggregates maintain a thermodynamically stable structure. The result is a stable, latex-like colloidal suspension of polymer aggregate particles having hydrophobic cores and hydrophilic coronas.
- Comb-type amphiphilic co-polymers differ from block co-polymers in that the backbone is largely hydrophobic or hydrophilic, with polymer chains of opposite polarity pendant from the backbone rather than incorporated into it.
- Comb-type copolymers have been prepared with hydrophobic backbones and hydrophilic branches (Mayes et al., US Patent No. 6,399,700), and also with hydrophilic backbones and hydrophobic branches (Watterson et al., U.S. Patent No. 6,521,736). The former were used to provide multivalent presentation of ligands for cell surface receptors, while the latter were used to solubilize drugs and deliver them to cells.
- Amphiphilic polymer aggregates have been studied as carriers for solubilizing insoluble drugs, targeted drug delivery vehicles, and gene delivery systems. They spontaneously self-assemble into a core-corona structure that is more stable than conventional low-molecular-weight micelles, due to chain entanglement and/or the crystallinity of the interior hydrophobic region.
- the polymeric nature of the vehicle renders the aggregates relatively immune to the disintegration that ordinary liposomes suffer when diluted below their critical micelle concentration.
- the absence of a bilayer membrane enables them to more readily fuse with cell membranes and deliver their payload directly to the cell.
- the amphiphilic nature of the aggregates also confers detergent-like activity, and appropriately targeted aggregates appear to be capable fusing with and disrupting viral coat proteins.
- PEG-conjugated polyamidoamine (“PAMAM”) dendrimers suitable for delivery of polynucleotides.
- Comb-type polymers generated by random functionalization or co-polymerization are mixtures of thousands of different species of differing molecular weights and branching patterns.
- the absence of a single, consistent structure presents problems in characterization and quality control, and can be an obstacle when regulatory approval is sought.
- Regular, consistently-structured amphiphilic comb polymers have been introduced to overcome this shortcoming (Diwan et al., U.S. Patent No. 8,173,764), but there remains a need for tight control of the molecular weight of such polymers.
- the present invention provides improved biocompatible comb-type polymers of structure (4) below, and methods for producing the improved polymers.
- the value of m ranges from 10 to 50 and is preferably between 20 and 25.
- the value of n ranges from 5 to 25, and the overall molecular weight of the polymer (4) may range from 2,000 to 25,000 daltons, and is preferably between 5,000 and 15,000 daltons.
- R represents a mixture of H and C8-C18 hydrophobic side chains, with the proportion of H ranging from 30% to 90%, preferably 40-90%, and more preferably 50-90%.
- the invention provides aqueous suspensions of core-corona nanoparticles, which self-assemble from the polymer (4), and provides methods for solubilizing antiviral drugs, by incorporating such drugs (and prodrugs thereof) in the hydrophobic cores of the polymer particles.
- the invention further provides hydrophobic prodrugs tailored to be soluble in the hydrophobic cores of the nanoparticles.
- the invention provides polymers (4) to which a plurality of viral -targeting ligands have been covalently attached. Attachment of ligands to the repeating units of the polymers of the invention affords multivalent display of the ligand on the polymer chain and on the nanoparticles surface.
- the invention also provides a method for the treatment or prevention of an infection of an animal by a virus, which comprises administering to said animal a suspension of corecorona type nanoparticles which comprise a comb-type polymer having structure (4).
- the polymer particles preferably have an antiviral drug or prodrug dissolved or dispersed in the hydrophobic nanoparticle core.
- the self- assembled nanoparticles have inherent antiviral properties.
- This antiviral activity is thought to be due to the detergent-like ability of the amphiphilic polymers to disrupt the outer coating of virus particles. This activity is enhanced by the binding affinity of the multiple carboxylate groups for the surface of the targeted virus.
- the invention further provides methods for the preparation of the polymers, nanoparticles, and drug complexes described herein.
- the polymers of the invention self-assemble into polymer aggregates that efficiently solubilize, distribute, and deliver drugs in vivo; have inherent antiviral activity; and are non-toxic, biocompatible, and stable.
- the invention also relates to a method for the treatment of viral diseases comprising the administration of antiviral agents encapsulated in the self-assembled nanoparticles of the invention.
- the invention also concerns pharmaceutical compositions comprising antiviral agents encapsulated in the self-assembled nanoparticles of the invention, and the use of these compositions for the treatment of viral diseases and more particularly for the treatment of infections caused by coronaviruses like SARS-CoV-2.
- the formulations provide a marked improvement in the pharmacokinetics of the encapsulated drugs and improve their aqueous solubility. The improvements in distribution and solubility enable the administration of a wide variety of prodrugs that would not otherwise be effective.
- Fig. 1 is a graph showing the molecular weight of pi-polymer as a function of the ratio of DTT to PEG dimaleate.
- Fig. 2 is a synthetic scheme for preparing the polymers of the invention.
- Fig. 3 is the legend for Fig. 2, and identifies the R groups.
- the polymers of the invention have a comb-type architecture, with a backbone formed of alternating branch-point moieties and hydrophilic, water-soluble PEG blocks; and a plurality of hydrophobic side chains R attached to each branch-point moiety, as shown in Formula (4).
- the hydrophobic side chains R are preferably C8 to C18 alkyl groups, but may incorporate heteroatoms to provide dipole-dipole or hydrogen-bonding interactions with encapsulated drugs or prodrugs. Ether, ester, amide, sulfoxide and sulfonyl groups, for example, can be incorporated into some or all of the groups R.
- the improved polymers of the present invention feature a narrow molecular weight distribution, controlled chain terminal structures, a lowered level of hydrophobic substituents R, and a high density of carboxylate groups, which act as affinity ligands for viral coat proteins.
- the polymers having lower levels of hydrophobic substitution e.g., 30%. 40% or 50% of R being hydrophobic have been found to be more water-soluble, and more suitable for injectable formulations.
- Attachment of ligands to the repeating units of the polymers of the invention affords multivalent display of the ligand on the polymer chain and on the nanoparticles surface, which can result in great increases in affinity for the ligands’ target.
- multivalent antibodies can be far more effective in clearance of their targets than the normal divalent antibodies.
- Carbohydrate-binding proteins and carbohydrates are known to be multivalent in nature, and ineffective if monovalent.
- multivalent peptide and carbohydrate targeting moieties will be far more effective than the monomer alone.
- the increase in MW due to attachment to the polymer results in reduced renal clearance rates of peptides and other ligands.
- the PEG backbone affords to the peptide benefits similar to those of PEGylation, including evasion of immune surveillance.
- a multivalent targeting moiety will decorate a multivalent target (say, a virus particle) and neutralize it far more effectively than the monomeric targeting moiety.
- the invention provides a comb polymer having the following structure:
- each instance of R is individually either OH or a C8-C18 hydrophobic moiety
- each instance of L is individually either OH or a ligand having specific binding affinity for the surface of a virus.
- the average value of m ranges from 10 to 50; and the average value of n ranges from 5 to 25.
- Each ligand L is may be, for example, one of the following moieties:
- each R1 is individually H or C1-C4 alkyl
- each R2 is individually H, COR1, or CO 2 R1.
- the comb polymers described above When dissolved in water or an aqueous medium, the comb polymers described above self-assemble into core-corona nanoparticles.
- the invention provides such nanoparticles having dissolved or dispersed within their hydrophobic cores an antiviral drug or a prodrug thereof.
- compositions which comprise a pharmaceutically acceptable aqueous carrier and the core-corona nanoparticles described above, both with and without antiviral drugs or pro-drugs dissolved therein.
- the invention provides a method of treating or preventing viral infections in animals (including humans) by administering the comb polymers and pharmaceutical compositions described above, in particular infections by coronaviruses, including SARS-CoV-2.
- the polymers of the invention may be prepared by the process shown in Scheme 1 and in Figure 2. In practice, the chemical reactions illustrated proceed with statistical product distributions and with less-than-perfect efficiency, and it should be understood that the polymer products shown in the schemes and in the claims are ideal representations rather than typical or average structures. For example, in the treatment of 3 with maleic anhydride (step D in Figure 2), the yield of adduct ranges from 30-50%, which the inventors believe is due to competing Michael addition of side chain hydroxyl groups to form lactone rings.
- step E in Figure 2 The subsequent reaction with mercaptosuccinic acid (step E in Figure 2) may proceed with yields ranging from 20% to 100%, depending upon the amount of reagent, time, and temperature; these variables can be manipulated to control the density of carboxyl groups on the final product.
- the invention thus encompasses compositions that are mixtures of regioisomers at the succinate moieties. Due to the asymmetric carbons at the sulfur-bearing carbons, the invention also encompasses polymers which contain mixtures of any or all of the possible regio- and stereo-isomeric possibilities.
- the hydrophobic moieties R are preferably derived from C8 to Cl 8 aliphatic amines RNH2, and are most conveniently linked to the polymer by amidation of the carboxylic acid groups of polymer (2) as illustrated in Scheme 1.
- the hydrophobic groups R are preferably C8-C20 hydrocarbon moieties, which may be linear or branched or contain one or more rings. Examples of the group R include but are not limited to n-octyl, 2-ethylhexyl, n-dodecyl, n-hexadecyl, and the like.
- the solvent power of the hydrophobic core of the self-assembled nanoparticles can be increased by introducing halogen, ether, ester, amide, or nitrile moieties into the hydrophobic group R.
- hydrophobic when applied to R means that the logP value (octanol -water) of the molecule R-H is greater than 2. In preferred embodiments, logP is greater than 2.5.
- the invention provides processes for the preparation of the comb polymers of the invention.
- the key starting material is polyethylene glycol, which is preferably dried before use by stirring under vacuum at an elevated temperature. This may take 8-12 hours, depending on the quality of the PEG. Once dried, the PEG can be stored under argon indefinitely.
- the PEG is preferably of low dispersity.
- PEG polymers that are >95% monodisperse, such as are commercially available from Nektar Therapeutics (formerly Shearwater Polymers), Huntsville AL, and Polypure AS, Oslo, Norway.
- An example of a monodisperse PEG is “PEG-28” from Polypure, which is >95% H0(CH2CH20)28H, molecular weight 1252.
- Polyethylene glycol 1000 for synthesis available from Millipore Sigma, Burlington MA, is suitable.
- a repreesentative plot is shown in Fig. 1.
- the DTT/PEG dimaleate ratio required to obtain a desired MW from this particular batch PEG dimaleate can be obtained from this plot, and by using this ratio in the production process, the desired MW is reliably achieved.
- the plot is considered a specific characteristic associated with the given batch of PEG dimaleate under the specified process conditions. For a different batch of PEG dimaleate, the process is repeated and a new plot generated, so as to provide the operating polymerization characteristic for that batch.
- PM2-DTT polymer (2) [41] PEG dimaleate (1) (“P10M2”) was prepared from polyethylene glycol 1000 using the method described in US 2010/0260743. The polymer was melted under nitrogen at 60- 80°C, water was added to 40-50% w/v final concentration, and the solution was adjusted to pH 6-8.5 by addition of DIPEA. Dithiothreitol (DTT), 1.02 to 1.5 mmol per mmol of maleate double bonds, was added as a solution or as a solid. The molar ratio of DTT to P10M2 was based on the desired MW of the P10M2-DTT polymer (2).
- DTT Dithiothreitol
- the pH of the solution was monitored by a pH probe and viscosity was monitored using in-reactor ultrasonic viscometer probe. The viscosity plateaued in about 15 minutes and remained essentially unchanged for next 30 minutes. Unreacted DTT and terminal sulfhydryl groups were quenched by the addition of maleic acid until the mixture gave a negative test with Ellman’s reagent.
- the reaction mixture was acidified to pH 2-4 with 6 N hydrochloric acid.
- the product PI 0M2- DTT (2) was purified by extraction into dichloromethane (DCM); the low-molecular-weight impurities formed by reaction of DTT with maleic acid and salts remain in the aqueous layer and are removed.
- the DP (degree of polymerization) of the resulting polymer ranged from 3 to 10 as desired, based on the amount of DTT employed, and the molecular weight (as determined by SEC-MALS) ranged from 4kDa to 14 kDa.
- Dry polymer (2) (P10M2-DTT) is dissolved in a solvent such as dichloromethane and the carboxyl groups are activated by reaction with activation agents such as diisopropylcarbodiimide (DIC), N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride ( EDC.HCL ) or N,N’-carbonyldiimidazole (CDI).
- activation agents such as diisopropylcarbodiimide (DIC), N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride ( EDC.HCL ) or N,N’-carbonyldiimidazole (CDI).
- N-hydroxysuccinimide and N-hydroxysulfosuccinimide are used, particularly with carbodiimide reagents, to minimize side reactions, such as the conversion of reactive O-acyl ureas to
- the molar equivalents of activating agent used depends on the alkyl amine substitution; desired and maximum amine substitution are not more than the equivalents of activating agent used.
- the activation time can be between 15 minutes and 2 hrs.
- alkyl amines such as hexadecylamine (HD A), tetradecylamine and other C8 to Cl 8 alkyl amines, 0.1 to 0.2 molar excess of activating agent are used.
- the amidation reaction is carried out between 20- 60°C, preferably between 30-50°C, depending upon the amine. Larger amines were found to react better at higher temperatures, possibly because of micelle fomation in the reaction mixture at lower temperatures.
- the reaction is quenched with water or acidified water to decompose residual activated carboxy groups, and the amidated polymer (3) is extracted into DICHLOROMETHANE or a suitable water immiscible solvent, and washed with water and dilute acid to remove water-soluble and basic impurities.
- the amidated polymer is further freed from residual alkyl amine by treating with a strong cation exchange resin, and the solvent is removed by distillation in vacuo.
- Apparent molecular weights are determined by SEC-MALS.
- the alkyl amine content is determined by acid hydrolysis of the polymer, followed by estimation of alkyl amine by reaction with a suitable amine reactive reagent such as fluorescamine. Unreacted carboxylic groups are estimated by determination of the polymer’s acid value.
- P10M2-DTT (1 mmol carboxy groups) was dissolved in DICHLOROMETHANE in a reactor set up with a stirrer, a condenser and a thermometer. The solution pH was adjusted to 2-4 with a tertiary base such as triethylamine or diisopropylethylamine. Carbonyldiimidazole (CDI, 0.5 mmol) was added with stirring at a temperature of 10-30°C, controlling the evolution of carbon dioxide generated. The reaction mixture was stirred at ambient temperature for 15-60 minutes to activate the carboxy groups on the polymer. To the activated polymer was then added n-hexadecylamine (HD A, 0.55-0.65 mmol).
- HD A n-hexadecylamine
- the reaction was stirred at 20-45°C for 2-18 hours, or until the TLC or mass spectroscopy of the reaction mixture showed the desired progress of the reaction.
- the reaction was terminated by careful addition of aqueous HC1 to decompose residual activated carboxylates. Additional aqueous HC1 was added, and the aqueous layer (containing imidazole, water-soluble salts, and other water-soluble impurities) was removed. The isolated organic phase was washed again with water.
- Ethanol was added to a 30-60% final concentration, and the polymer solution was treated (in column or in batch mode) with a strong cation exchange resin (H+ form, 3 to 10 equivalents per equivalent of hexadecylamine) to remove the unreacted amine.
- a strong cation exchange resin H+ form, 3 to 10 equivalents per equivalent of hexadecylamine.
- the efficiency of removal of amine was followed by TLC and mass spectral analysis.
- the product was isolated by distillation of the dichloromethane-ethanol solvent in vacuo, to give P10M2-DTT-C16 (3) as a waxy solid.
- P10M2-DTT-C16 (3) is heated to 90-120°C under a nitrogen atmosphere, to form a stirrable melt, and a solution of maleic anhydride (1.0 equivalents per equivalent of hydroxy groups) in methyl isobutyl ketone is added. The reaction mixture is stirred at 90-140°C to form the maleate esters of the DTT hydroxyl groups.
- reaction mixture is then cooled to about 40-70°C, diluted with water, and the pH raised to 8-9 by addition of DIPEA.
- Mercaptosuccinic acid (1 equivalent per equivalent of maleic anhydride) is then added, and allowed to react with the maleate double bonds at pH 8- 9.
- the reaction mixture is then cooled to room temperature and extracted with 1 : 1 dichloromethane-isopropyl acetate to remove low molecular weight organic contaminants.
- the pH is adjsuted to between 2 and 4 with hydrochloric acid, and the polymer (“P10M2- DTT-C16-(M-MSA)”) is extracted from water into DICHLOROMETHANE, and precipitated by addition of 1-4 volumes of n-heptane.
- the solid is dissolved in butanol or isoamyl alcohol, and re-precipitated by addition of n-heptane.
- the representative virus-targeting ligands disclosed below have a primary amino group that is used to conjugate the ligand with the polymer carboxylic acids to give the active drug.
- the methods illustrated are representative, and other means of attachment will be apparent to those of skill in the art, using any of the many linkers and coupling reactions known in the field of small molecule-polymer conjugates.
- the ligands presented here fall into a few categories:
- Methyl 6-chloronicotinate is dissolved in THF or MEK as solvent.
- a molar equivalent of Boc-l-cysteine methyl ester is added followed by addition of potassium carbonate or a tertiary organic base such as triethylamine or DIPEA.
- Water is added to precipitate the product as a solid, which is isolated by filtration.
- the filter cake is washed with methanol-water.
- the dried product is dissolved in dichloromethane and then treated with HC1 in dioxane to remove the t-Boc group.
- the product is isolated as a hydrochloride salt.
- cysteic amide derivative (general procedure): Boc-l-cysteic acid and the nicotinyl ester (a) above are dissolved in dimethylformamide. The pH is adjusted with triethylamine to 7-8. A slight molar excess N-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC.HC1) or 4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) is added with an equivalent amount of N-hydroxysuccinimide. After the reaction is complete, the mixture is partitioned between ethyl acetate and aqueous sodium carbonate. The cysteic amide is preciptated from the aqueous solution by neutralization.
- EDC.HC1 N-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
- DTMM 4-(4,6-dime
- the de-esterified material is extracted into alkali, and acidified to pH 3-5 to precipitate the acid as a solid, which is isolated by filtration to yield caffeoyl-lysine(Boc)-OH.
- the Boc group is then removed as described above.
- the caffeic acid (b) is amidated with cysteic acid as described above.
- the product is purified by water washes.
- the protective t-Boc group is then removed with HCl-dioxane as described earlier.
- This compound is prepared from L60(OMe)2 and Boc-l-cysteic acid by the general procedure described earlier.
- the t-boc protection group is removed by HCl-dioxane using the general procedure described.
- the above ligands are illustrated as their methyl esters, but ethyl, n-propyl, and butyl esters are contemplated as well.
- One or both catechol OH groups of caffeic acid may esterified, as carboxymethyl, carboxyethyl), acetate, propionate, and the like.
- Standard peptide coupling techniques are used to activate carboxy groups of polymers (4) with carbonyldiimidazole or N,N-diisopropylcarbodiimide, followed by addition of the desired ligand.
- the various virus-specific ligands described above can be conjugated to the polymer through amide linkages.
- the amounts of ligand can be varied as desired.
- a representative structure (5) is illustrated above, where L represents a ligand coupled via amidation of the polymer carboxyl groups. Coupling to the least sterically hindered carboxyl groups is illustrated, but it will be appreciated that any of the available carboxy groups, including those at the polymer end caps, may be amidated.
- a suitable inert solvent such as DMF under an atmosphere of nitrogen
- the pH is adjusted to 3.5-4.5 with hydrochloric acid, followed by excess water to precipitate the polymer-ligand conjugate.
- the polymer-ligand conjugate is then purified by either solvent-water extractions or by dialysis or tangential flow filtration with an appropriate cut-off membrane.
- the host polymer and the guest drug are dissolved, in proportions from 3: 1 to 20: 1, in a mutual solvent, such as dimethylsulfoxide (DMSO), ethanol, tetrahydrofuran (THF) or dichloromethane (DCM), and mixed to produce a clear solution.
- a mutual solvent such as dimethylsulfoxide (DMSO), ethanol, tetrahydrofuran (THF) or dichloromethane (DCM)
- DMSO dimethylsulfoxide
- THF tetrahydrofuran
- DCM dichloromethane
- This solution is then evaporated in an oven or on a rotary evaporator, or lyophilized, depending upon the solvent used.
- the dried mixture is then reconstituted in water or suitable buffer to give an emulsion of the guest drug distributed within the self-assembled polymer nanoparticles.
- the loading ratio of the guest drug is then determined by suitable method such as HPLC or UV-Visible spectroscopy.
- the self-assembled nanoparticles by virtue of having a hydrophobic core, are capable of dissolving or suspending hydrophobic drugs and pro-drugs that are otherwise not readily formulated into effective pharmaceutical compositions. They enable pro-drugs to be designed for optimal pharmacokinetics, without having to make compromises in the interest of aqueous solubility and bioavailability.
- Many alkyl and alkoxycarbonyl prodrugs are known in the art, and methods for their manufacture are well known and largely routine. Representative examples are provided below, but most known methods can be adapted to a variety of substrates.
- esters of Cl to Cl 8 aliphatic and aromatic acids carbonates derived from Cl to Cl 8 aliphatic and aromatic alcohols, and carbamates derived from Cl to Cl 8 aliphatic and aromatic amines, is considered to be within the scope of the invention.
- the invention makes possible the administration of hydrophobic drugs and prodrugs that might not otherwise be considered as clinical candidates.
- Suitable antiviral drugs, pro-drugs and drug candidates for use in the invention include, but are not limited to, remdesivir, acyclovir, molnupiravir, PF-00835231, ivermectin, colcicine, mebendazole, CDI-45205, and GC-376, and various prodrug esters, amides and carbamates thereof.
- a 10-20 % w/w solution of P10M2-DTT-C16-(M-MSA) polymer (4) is prepared in ethyl alcohol. Solid remdesivir, 5 to 20 % by weight of polymer used, is added to the polymer solution. The mixture is well stirred to dissolve remdesivir and then evaporated to dryness under nitrogen at 35-60°C until constant weight is observed. The dried material is then dissolved in PBS or water at pH 6-7, and filter-sterilized for further use. The concentration of remdesivir is determined by HPLC or UV analysis.
- the new and known drug derivatives (i.e. pro-drugs) of the invention which are lower alkyl esters or lower alkoxy carbonyl esters (i.e. carbonates) of antiviral drugs known in the art, are prepared by analogous methods.
- Alkoxycarbonyl chlorides may be employed to prepare alkoxycarbonyl esters, and in those cases the preferred solvents are DMF or NMP.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des polymères en peigne amphiphiles améliorés, comprenant un squelette hydrophile avec des fractions hydrophobes pendantes espacées régulièrement, ayant des masses moléculaires bien contrôlées, des structures et des groupes terminaux. Les polymères s'auto-assemblent en nanoparticules noyau-couronne dans des environnements aqueux, qui sont susceptibles de perturber des protéines d'enveloppe virale, et qui sont susceptibles d'encapsuler des médicaments antiviraux et des promédicaments. Des fractions de ciblage espacées régulièrement assurent éventuellement la médiation de l'adhérence des nanoparticules à l'enveloppe virale.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/039050 WO2022271183A1 (fr) | 2021-06-25 | 2021-06-25 | Polymères amphiphiles à auto-assemblage en tant qu'agents anti-covid-19 |
AU2022297600A AU2022297600A1 (en) | 2021-06-25 | 2022-06-28 | Self-assembling amphiphilic polymers as anti-covid-19 agents |
BR112023027392A BR112023027392A2 (pt) | 2021-06-25 | 2022-06-28 | Polímeros anfifílicos automontáveis como agentes anti-covid-19 |
CA3224103A CA3224103A1 (fr) | 2021-06-25 | 2022-06-28 | Polymeres amphiphiles a auto-assemblage utilises en tant qu'agents anti-covid-19 |
IL309697A IL309697A (en) | 2021-06-25 | 2022-06-28 | Self-assembled amphiphilic polymers as anti-COVID-19 agents |
PCT/US2022/035210 WO2022272181A1 (fr) | 2021-06-25 | 2022-06-28 | Polymères amphiphiles à auto-assemblage utilisés en tant qu'agents anti-covid-19 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/039050 WO2022271183A1 (fr) | 2021-06-25 | 2021-06-25 | Polymères amphiphiles à auto-assemblage en tant qu'agents anti-covid-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022271183A1 true WO2022271183A1 (fr) | 2022-12-29 |
Family
ID=84545895
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/039050 WO2022271183A1 (fr) | 2021-06-25 | 2021-06-25 | Polymères amphiphiles à auto-assemblage en tant qu'agents anti-covid-19 |
PCT/US2022/035210 WO2022272181A1 (fr) | 2021-06-25 | 2022-06-28 | Polymères amphiphiles à auto-assemblage utilisés en tant qu'agents anti-covid-19 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/035210 WO2022272181A1 (fr) | 2021-06-25 | 2022-06-28 | Polymères amphiphiles à auto-assemblage utilisés en tant qu'agents anti-covid-19 |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU2022297600A1 (fr) |
BR (1) | BR112023027392A2 (fr) |
CA (1) | CA3224103A1 (fr) |
IL (1) | IL309697A (fr) |
WO (2) | WO2022271183A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399700B2 (en) * | 1998-04-13 | 2002-06-04 | Massachusetts Institute Of Technology | Comb copolymers for regulating cell-surface interactions |
US6521736B2 (en) * | 2000-09-15 | 2003-02-18 | University Of Massachusetts | Amphiphilic polymeric materials |
US8173764B2 (en) * | 2006-01-19 | 2012-05-08 | Allexcel Inc. | Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006833A1 (fr) * | 1995-08-11 | 1997-02-27 | Dendritech, Inc. | Conjugues de polymeres hyper-ramifies en peigne |
WO2006113666A2 (fr) * | 2005-04-19 | 2006-10-26 | Massachusetts Institute Of Technology | Polymeres amphiphiles et leurs procedes d'utilisation |
MX2009005345A (es) * | 2007-01-22 | 2009-06-12 | Allexcell Inc | Polimeros anfifilicos de autoensamblaje como agentes antivirales. |
EP2167103B1 (fr) * | 2007-07-19 | 2017-03-01 | Allexcel, Inc. | Polymères amphiphiles à auto-assemblage en tant qu'agents anticancer |
US20180016352A1 (en) * | 2015-02-05 | 2018-01-18 | The University Of Queensland | Targeting constructs for delivery of payloads |
-
2021
- 2021-06-25 WO PCT/US2021/039050 patent/WO2022271183A1/fr unknown
-
2022
- 2022-06-28 AU AU2022297600A patent/AU2022297600A1/en active Pending
- 2022-06-28 WO PCT/US2022/035210 patent/WO2022272181A1/fr active Application Filing
- 2022-06-28 CA CA3224103A patent/CA3224103A1/fr active Pending
- 2022-06-28 BR BR112023027392A patent/BR112023027392A2/pt unknown
- 2022-06-28 IL IL309697A patent/IL309697A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399700B2 (en) * | 1998-04-13 | 2002-06-04 | Massachusetts Institute Of Technology | Comb copolymers for regulating cell-surface interactions |
US6521736B2 (en) * | 2000-09-15 | 2003-02-18 | University Of Massachusetts | Amphiphilic polymeric materials |
US8173764B2 (en) * | 2006-01-19 | 2012-05-08 | Allexcel Inc. | Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers |
Also Published As
Publication number | Publication date |
---|---|
AU2022297600A1 (en) | 2024-02-01 |
BR112023027392A2 (pt) | 2024-03-12 |
IL309697A (en) | 2024-02-01 |
WO2022272181A1 (fr) | 2022-12-29 |
CA3224103A1 (fr) | 2022-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Almeida et al. | Novel amphiphilic chitosan micelles as carriers for hydrophobic anticancer drugs | |
EP2516502B1 (fr) | Polymères séquencés biodégradables pour l'administration de médicament et procédés associés à ceux-ci | |
Hu et al. | Targeting and anti-tumor effect of folic acid-labeled polymer–doxorubicin conjugates with pH-sensitive hydrazone linker | |
US20230279186A1 (en) | Hydrogels Based On Functionalized Polysaccharides | |
Yu et al. | Self-assembly of pH-responsive biodegradable mixed micelles based on anionic and cationic polycarbonates for doxorubicin delivery | |
Abbasi et al. | Polyacrylamide–b-copolypeptide hybrid copolymer as pH-responsive carrier for delivery of paclitaxel: Effects of copolymer composition on nanomicelles properties, loading efficiency and hemocompatibility | |
Le et al. | Facile approach to prepare pH and redox-responsive nanogels via Diels-Alder click reaction | |
Liu et al. | Synthesis and self-assembly of chitosan-based copolymer with a pair of hydrophobic/hydrophilic grafts of polycaprolactone and poly (ethylene glycol) | |
Khuphe et al. | Glucose-bearing biodegradable poly (amino acid) and poly (amino acid)-poly (ester) conjugates for controlled payload release | |
JP4314229B2 (ja) | 温度感応性及び生体適合性を有する両親媒性環状ホスファゼン三量体及びその製造方法 | |
US20180326074A1 (en) | Methods for synthesizing peptide-tagged pegylated chitosan | |
Jang et al. | Characterization and modification of low molecular water-soluble chitosan for pharmaceutical application | |
WO2022271183A1 (fr) | Polymères amphiphiles à auto-assemblage en tant qu'agents anti-covid-19 | |
CN104371098A (zh) | 多分支亲水性聚合物-异氰酸酯衍生物 | |
Cai et al. | pH-sensitive nanoparticles self-assembled from a novel class of biodegradable amphiphilic copolymers based on chitosan | |
Stanciu et al. | New biocompatible amphiphilic diblock copolymer based on dextran | |
CN109679073B (zh) | 一种hpma-nas-pla聚合物及其制备方法和应用 | |
Kim et al. | Synthesis and characterization of novel amino acid-conjugated poly (aspartic acid) derivatives | |
Fu et al. | pH-responsive star-shaped functionalized poly (ethylene glycol)-b-poly (ε-caprolactone) with amino groups | |
Dai Hai | 5-fluorouracil encapsulated CS-mPEG nanogels for controlling drug release | |
EP3295933A1 (fr) | Hydrogels à base de polysaccharides fonctionnalisés | |
US11179475B2 (en) | Biodegradable functional polycarbonate nanoparticle carries for delivering molecular cargo | |
Lanz-Landázuri et al. | Modification of microbial polymers by thiol-ene click reaction: Nanoparticle formation and drug encapsulation | |
Kabil et al. | Recent progress on polySarcosine as an alternative to PEGylation: Synthesis and biomedical applications | |
EP4114870A1 (fr) | Macromolécules amphiphiles d'alginate-acide oléique et leur procédé de préparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21947347 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |